Kimberly-Clark To Acquire Tylenol-Maker Kenvue In Giant $40 Billion Merger
Consumer products company Kimberly-Clark Corporation announced it will acquire Tylenol maker Kenvue in a cash-and-stock transaction valued at nearly $49 billion, marking one of the largest consumer health mergers in history.
Kimberly-Clark revealed in a press release that the deal values Kenvue at 14.3x its latest twelve months (LTM) adjusted EBITDA. In return, Kenvue shareholders will receive $3.50 in cash and .14625 Kimberly-Clark shares per Kenvue share, for a total of about $ 21.01 per share. The deal is valued at $48.7 billion.
The deal is expected to close in 2H 2026. Upon completion, Kimberly-Clark shareholders will own 54% of the combined company, while Kenvue shareholders will own 46%. Both boards have unanimously approved the acquisition. JPMorgan Chase is providing committed financing for the deal.